Form 4: Director Leonard Post Executes Stock Option Plan

Director Leonard Post exercised 1,000 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Summary

• Director Leonard Post exercised 1,000 stock options at a strike price of $0.60 per share.
• The resulting 1,000 shares of common stock were sold at a price of $54.50 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2026.
• Following the transaction, the director was granted a new stock option for 9,354 shares at an exercise price of $56.09.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard portfolio management by a director.

Positives

• The director maintains a significant ongoing equity interest in the company through remaining derivative holdings.
• Transactions were conducted via a pre-arranged Rule 10b5-1 plan, indicating systematic rather than reactive trading.

Negatives

• The director liquidated a portion of their holdings, resulting in a zero balance of common stock held directly following the sale.

Risks

• Future vesting of the new 9,354 share option grant is subject to the director's continuous service to the issuer.

Future Outlook

The director received a new grant of 9,354 stock options which vest monthly over 12 months, or upon the next annual meeting of stockholders, provided continuous service is maintained.

Industry Context

StockSavvy.ai notes that routine insider selling via Rule 10b5-1 plans is standard corporate governance practice for directors in the biotechnology sector to manage personal liquidity while maintaining long-term alignment with shareholders.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a best-practice standard for corporate insiders to avoid allegations of trading on material non-public information.
• The vesting schedule for the new options aligns with typical director compensation structures in the mid-cap biotech industry.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was executed under a pre-established trading plan.

Next Steps

• Vesting of the 9,354 stock options granted on June 4, 2026, subject to continuous service.

Key Dates

Keywords

CG Oncology, CGON, Insider Trading, Form 4, Stock Options, Director Transaction